Amplicor hiv monitor test

This study evaluated 44 HIV-positive and 81 HIV-negative subjects retrospectively selected from the HIV Neurobehavioral Research Center (HNRC)’s Prospective Memory cohort29 (link). The parent study enrolled a total of 212 HIV-infected participants (without restrictions on ART status) between May 2008 and February 2013, and was designed to investigate the combined effects of age (in groups ≤40 and ≥50 years old) and HIV disease on NCI. HIV-infected participants on ART with suppressed HIV RNA levels in blood (<50 copies/μL of plasma) and with available paired blood and CSF samples qualified for this study. Blood CD4 + T lymphocyte subsets were measured by flow-cytometry (CLIA certified local laboratories), and HIV RNA levels were quantified by the Amplicor HIV Monitor Test (Roche Molecular Systems Inc.). HIV negative controls were matched by age, sex and ethnic identity to their HIV infected counterparts.

We evaluated 29 HIV infected subjects from the UCSD HIV Neurobehavioral Research Center (HNRC) cohort. Participants were retrospectively selected based on the availability of peripheral blood mononuclear cells (PBMC) and CSF cell pellets. Participants were selected to represent groups on and off ART, and to span a range of HIV RNA levels in blood and CSF supernatant. Samples with levels of HIV RNA in blood plasma and CSF bellow 48 copies/mL were considered undetectable. The CNS penetration effectiveness (CPE) index for the most recent ART regimen was determined as previously described [11 ]. Blood CD4+ T-lymphocyte subsets were measured by flow-cytometry (CLIA certified local laboratory). HIV RNA levels were quantified by the Amplicor HIV Monitor Test (Roche Molecular Systems Inc.). We also selected 20 CSF cellular pellets from HIV negative subjects to be used as negative controls for ddPCR. All participants provided appropriate written informed consent and the study was approved by Human Research Protections Program at University of California San Diego.